Alkermes
today agenda harnessing the potential of the pathway advancing a differentiated alfa molecular design clinical development strategy clinical data overview artistry intravenous dosing focus on melanoma and platinum resistant ovarian cancer artistry subcutaneous dosing subcutaneous recommended phase dose and preliminary objective response upcoming data and next steps alkermes | Alkermes
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
56 of 144
Related slides by other companies
argenx SE
Results
July 2021
data support favorable benefit to risk ratio four indications clinical proof of concept in no evidence of dose limiting | argenx SE
Certara
Investor Day
December 2021
case study using simulator | Certara
Certara
Investor Day
December 2021
assuring and accelerating regulatory success | Certara
Arbutus Biopharma
Investor Presentation
August 2023
clinical trial key | Arbutus Biopharma
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io